APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II
August 23, 2023 17:21 ET
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...
The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030, growing at an annualized rate of 27.54% during the period 2021-2030, claims Roots Analysis
September 22, 2021 09:00 ET
|
Roots Analysis
London, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Soft Tissue Sarcoma Market: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report...
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)
June 30, 2021 07:00 ET
|
Retrotope
LOS ALTOS, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)
February 18, 2020 16:10 ET
|
Retrotope
LOS ALTOS, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation...
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
December 13, 2019 07:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear...
Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
October 03, 2018 07:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s...
Alectos Therapeutics Announces FDA Orphan Drug Designation for MK-8719: An Investigational Small-molecule OGA Inhibitor for Treatment of Progressive Supranuclear Palsy
April 20, 2016 09:00 ET
|
Alectos Therapeutics Inc.
VANCOUVER, BRITISH COLUMBIA, April 20, 2016 (GLOBE NEWSWIRE) -- Alectos Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation...